Is Intelligent Bio Stock a Good Investment?
Intelligent Bio Investment Advice | INBS |
- Examine Intelligent Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Intelligent Bio's leadership team and their track record. Good management can help Intelligent Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Intelligent Bio's business and its evolving consumer preferences.
- Compare Intelligent Bio's performance and market position to its competitors. Analyze how Intelligent Bio is positioned in terms of product offerings, innovation, and market share.
- Check if Intelligent Bio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Intelligent Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Intelligent Bio Solutions stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Intelligent Bio Solutions is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Intelligent Bio Stock
Researching Intelligent Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 14.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.24. Some equities with similar Price to Book (P/B) outperform the market in the long run. Intelligent Bio Solutions recorded a loss per share of 2.3. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 29th of January 2024.
To determine if Intelligent Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Intelligent Bio's research are outlined below:
| Intelligent Bio is way too risky over 90 days horizon | |
| Intelligent Bio may become a speculative penny stock | |
| Intelligent Bio appears to be risky and price may revert if volatility continues | |
| Intelligent Bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 3.11 M. Net Loss for the year was (10.19 M) with profit before overhead, payroll, taxes, and interest of 326.67 K. | |
| Intelligent Bio Solutions currently holds about 8.28 M in cash with (9.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56. | |
| Intelligent Bio has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Revolutionary Fingerprint Drug Test Wins Major UK Contract, US Launch Next - StockTitan |
Intelligent Bio Quarterly Liabilities And Stockholders Equity |
|
Intelligent Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Intelligent Bio Solutions. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Intelligent Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of August 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Intelligent Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Intelligent Bio's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-09 | 2022-09-30 | -0.1 | -0.08 | 0.02 | 20 | ||
2024-11-07 | 2024-09-30 | -0.53 | -0.7 | -0.17 | 32 | ||
2023-08-23 | 2023-06-30 | -1.49 | -1.91 | -0.42 | 28 | ||
2024-05-08 | 2024-03-31 | -0.87 | -1.43 | -0.56 | 64 | ||
2022-08-31 | 2022-06-30 | -3.6 | -2.8 | 0.8 | 22 | ||
2024-09-19 | 2024-06-30 | -0.51 | -1.34 | -0.83 | 162 | ||
2024-02-09 | 2023-12-31 | -3.24 | -2.07 | 1.17 | 36 | ||
2022-05-10 | 2022-03-31 | -3.2 | -1.8 | 1.4 | 43 |
Know Intelligent Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Intelligent Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Intelligent Bio Solutions backward and forwards among themselves. Intelligent Bio's institutional investor refers to the entity that pools money to purchase Intelligent Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Hudson Bay Capital Management Lp | 2024-06-30 | 0.0 | Citigroup Inc | 2024-06-30 | 0.0 | Headlands Technologies Llc | 2024-06-30 | 0.0 | Jpmorgan Chase & Co | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 0.0 | Alyeska Investment Group, L.p. | 2024-09-30 | 206.2 K | Cvi Holdings Llc | 2024-06-30 | 79.8 K | Geode Capital Management, Llc | 2024-09-30 | 22.7 K | Vanguard Group Inc | 2024-09-30 | 15.5 K | Adar1 Capital Management Llc | 2024-09-30 | 5.4 K | Ubs Group Ag | 2024-09-30 | 1.6 K |
Intelligent Bio's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.14 M.Market Cap |
|
Intelligent Bio's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.97) | (1.02) | |
| Return On Capital Employed | (1.42) | (1.35) | |
| Return On Assets | (0.66) | (0.70) | |
| Return On Equity | (1.40) | (1.33) |
Determining Intelligent Bio's profitability involves analyzing its financial statements and using various financial metrics to determine if Intelligent Bio is a good buy. For example, gross profit margin measures Intelligent Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Intelligent Bio's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Intelligent Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Intelligent Bio Solutions. Check Intelligent Bio's Beneish M Score to see the likelihood of Intelligent Bio's management manipulating its earnings.
Evaluate Intelligent Bio's management efficiency
Intelligent Bio Solutions has return on total asset (ROA) of (0.5326) % which means that it has lost $0.5326 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7171) %, meaning that it created substantial loss on money invested by shareholders. Intelligent Bio's management efficiency ratios could be used to measure how well Intelligent Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.02 in 2025. Return On Capital Employed is likely to gain to -1.35 in 2025. At this time, Intelligent Bio's Other Current Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 1 M in 2025, whereas Total Current Assets are likely to drop slightly above 6.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.62 | 4.86 | |
| Tangible Book Value Per Share | 2.15 | 2.26 | |
| Enterprise Value Over EBITDA | 0.26 | 0.27 | |
| Price Book Value Ratio | 0.31 | 0.33 | |
| Enterprise Value Multiple | 0.26 | 0.27 | |
| Price Fair Value | 0.31 | 0.33 | |
| Enterprise Value | -2.9 M | -2.8 M |
Intelligent Bio's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Beta 4.724 |
Basic technical analysis of Intelligent Stock
As of the 1st of February, Intelligent Bio retains the Risk Adjusted Performance of 0.052, downside deviation of 5.09, and Market Risk Adjusted Performance of 0.1244. Intelligent Bio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Intelligent Bio Solutions information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Intelligent Bio is priced fairly, providing market reflects its last-minute price of 1.76 per share. Please also validate Intelligent Bio Solutions total risk alpha, which is currently at (0.31) to confirm the company can sustain itself at a future point.Intelligent Bio's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intelligent Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intelligent Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intelligent Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sakiris Spiro Kevin over two months ago Insider Trading | ||
Sakiris Spiro Kevin over six months ago Disposition of 9394 shares by Sakiris Spiro Kevin of Intelligent Bio subject to Rule 16b-3 | ||
Life Science Biosensor Diagnostics Pty Ltd over a year ago Sale by Life Science Biosensor Diagnostics Pty Ltd of 576028 shares of Intelligent Bio | ||
Towers Christopher over a year ago Purchase by Towers Christopher of 9090 shares of Intelligent Bio | ||
Sakiris Spiro Kevin over a year ago Intelligent Bio exotic insider transaction detected | ||
Sakiris Spiro Kevin over a year ago Intelligent Bio exotic insider transaction detected |
Understand Intelligent Bio's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Intelligent Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.052 | |||
| Market Risk Adjusted Performance | 0.1244 | |||
| Mean Deviation | 3.97 | |||
| Semi Deviation | 4.67 | |||
| Downside Deviation | 5.09 | |||
| Coefficient Of Variation | 1915.68 | |||
| Standard Deviation | 5.4 | |||
| Variance | 29.11 | |||
| Information Ratio | 0.0337 | |||
| Jensen Alpha | 0.0581 | |||
| Total Risk Alpha | (0.31) | |||
| Sortino Ratio | 0.0357 | |||
| Treynor Ratio | 0.1144 | |||
| Maximum Drawdown | 25.53 | |||
| Value At Risk | (7.97) | |||
| Potential Upside | 9.93 | |||
| Downside Variance | 25.91 | |||
| Semi Variance | 21.81 | |||
| Expected Short fall | (4.51) | |||
| Skewness | 0.5346 | |||
| Kurtosis | 1.2 |
| Risk Adjusted Performance | 0.052 | |||
| Market Risk Adjusted Performance | 0.1244 | |||
| Mean Deviation | 3.97 | |||
| Semi Deviation | 4.67 | |||
| Downside Deviation | 5.09 | |||
| Coefficient Of Variation | 1915.68 | |||
| Standard Deviation | 5.4 | |||
| Variance | 29.11 | |||
| Information Ratio | 0.0337 | |||
| Jensen Alpha | 0.0581 | |||
| Total Risk Alpha | (0.31) | |||
| Sortino Ratio | 0.0357 | |||
| Treynor Ratio | 0.1144 | |||
| Maximum Drawdown | 25.53 | |||
| Value At Risk | (7.97) | |||
| Potential Upside | 9.93 | |||
| Downside Variance | 25.91 | |||
| Semi Variance | 21.81 | |||
| Expected Short fall | (4.51) | |||
| Skewness | 0.5346 | |||
| Kurtosis | 1.2 |
Consider Intelligent Bio's intraday indicators
Intelligent Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Intelligent Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 63155.77 | |||
| Daily Balance Of Power | 0.8182 | |||
| Rate Of Daily Change | 1.11 | |||
| Day Median Price | 1.69 | |||
| Day Typical Price | 1.71 | |||
| Price Action Indicator | 0.16 | |||
| Period Momentum Indicator | 0.18 |
Intelligent Stock media impact
Far too much social signal, news, headlines, and media speculation about Intelligent Bio that are available to investors today. That information is available publicly through Intelligent media outlets and privately through word of mouth or via Intelligent internal channels. However, regardless of the origin, that massive amount of Intelligent data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Intelligent Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Intelligent Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Intelligent Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Intelligent Bio alpha.
Intelligent Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Intelligent Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Additional Tools for Intelligent Stock Analysis
When running Intelligent Bio's price analysis, check to measure Intelligent Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intelligent Bio is operating at the current time. Most of Intelligent Bio's value examination focuses on studying past and present price action to predict the probability of Intelligent Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intelligent Bio's price. Additionally, you may evaluate how the addition of Intelligent Bio to your portfolios can decrease your overall portfolio volatility.